- Home
- PRPH vs SABS Comparison
PRPH vs SABS Comparison
Compare PRPH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- SABS
- Stock Information
- Founded
- PRPH 1989
- SABS 2014
- Country
- PRPH United States
- SABS United States
- Employees
- PRPH N/A
- SABS N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- SABS Health Care
- Exchange
- PRPH Nasdaq
- SABS Nasdaq
- Market Cap
- PRPH 10.7M
- SABS 11.4M
- IPO Year
- PRPH 1997
- SABS N/A
- Fundamental
- Price
- PRPH $0.34
- SABS $1.38
- Analyst Decision
- PRPH
- SABS Strong Buy
- Analyst Count
- PRPH 0
- SABS 5
- Target Price
- PRPH N/A
- SABS $11.40
- AVG Volume (30 Days)
- PRPH 2.6M
- SABS 25.6K
- Earning Date
- PRPH 05-08-2025
- SABS 05-19-2025
- Dividend Yield
- PRPH N/A
- SABS N/A
- EPS Growth
- PRPH N/A
- SABS N/A
- EPS
- PRPH N/A
- SABS N/A
- Revenue
- PRPH $6,770,000.00
- SABS $1,322,410.00
- Revenue This Year
- PRPH $221.82
- SABS N/A
- Revenue Next Year
- PRPH N/A
- SABS $50.00
- P/E Ratio
- PRPH N/A
- SABS N/A
- Revenue Growth
- PRPH N/A
- SABS N/A
- 52 Week Low
- PRPH $0.22
- SABS $1.00
- 52 Week High
- PRPH $7.48
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- PRPH 50.38
- SABS 47.50
- Support Level
- PRPH $0.26
- SABS $1.30
- Resistance Level
- PRPH $0.38
- SABS $1.49
- Average True Range (ATR)
- PRPH 0.06
- SABS 0.12
- MACD
- PRPH 0.01
- SABS 0.04
- Stochastic Oscillator
- PRPH 48.85
- SABS 77.55
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.